Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Enliven Therapeutics Inc.

Healthcare US ELVN

46.13USD
5.77(14.30%)

Last update at 2026-06-12T20:07:00Z

Day Range

39.0047.36
LowHigh

52 Week Range

14.7948.53
LowHigh

Fundamentals

  • Previous Close 40.36
  • Market Cap2744.24M
  • Volume6145359
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-119.39500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.83

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -103.69400M -88.79200M -71.58400M -37.66200M -24.74000M
Minority interest - - - - -
Net income -103.69400M -89.02400M -71.58400M -37.75000M -24.71800M
Selling general administrative 33.80M 23.78M 18.95M 7.77M 4.29M
Selling and marketing expenses - - 18.94M - -
Gross profit -0.26300M -0.31700M -0.29700M - -
Reconciled depreciation 0.26M 0.32M 0.30M 0.21M 0.12M
Ebit -119.65800M -104.55400M -83.52900M -38.79100M -24.76200M
Ebitda -119.39500M -104.23700M -83.23200M -38.57600M -24.64700M
Depreciation and amortization 0.26M 0.32M 0.30M 0.21M 0.12M
Non operating income net other - - - - -
Operating income -119.65800M -104.55400M -83.52900M -38.79100M -24.76200M
Other operating expenses 119.66M 104.55M 83.53M 38.79M 24.76M
Interest expense - - - -1.21700M 0.09M
Tax provision 0.00000M 0.23M 0.00000M - -
Interest income 16.01M 14.89M 11.97M 1.13M 0.02M
Net interest income 16.01M 14.89M 11.97M 1.13M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.23M 1.30M 0.09M -0.02200M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 119.39M 104.55M 83.53M 38.79M 24.76M
Cost of revenue 0.26M 0.32M 0.30M - -
Total other income expense net 15.96M 15.76M 11.95M 1.13M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -103.69400M -89.02400M -71.58400M -37.66200M -24.74000M
Net income applicable to common shares - - - - -24.74000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 476.17M 325.76M 271.87M 83.30M 113.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 12.26M 4.69M 12.95M 2.22M 0.65M
Total liab 16.68M 15.91M 25.96M 160.12M 156.22M
Total stockholder equity 459.60M 309.85M 245.91M -76.82500M -42.88700M
Deferred long term liab - - - - 1.65M
Other current liab 14.01M 14.57M 25.03M 0.45M 0.37M
Common stock 0.06M 0.05M 0.04M 0.00100M 0.00100M
Capital stock 0.06M 0.05M 0.04M 0.00100M 0.00100M
Retained earnings -347.16600M -243.47200M -154.44800M -82.86400M -45.20200M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 1.71M
Cash 98.90M 124.12M 100.19M 75.54M 110.02M
Cash and equivalents - - - - -
Total current liabilities 16.57M 15.91M 25.89M 9.71M 5.75M
Current deferred revenue - - - 5.51M 2.70M
Net debt -98.49700M -124.11700M -99.86000M -75.21300M -109.86500M
Short term debt 0.40M - 0.34M 0.32M 0.16M
Short long term debt - - - - -
Short long term debt total 0.40M - 0.34M 0.32M 0.16M
Other stockholder equity 806.37M 553.21M 128.31M 6.04M 2.31M
Property plant equipment - - - - 0.95M
Total current assets 474.88M 318.13M 266.15M 77.75M 110.67M
Long term investments - - - - -
Net tangible assets - - - - -42.88700M
Short term investments 363.73M 189.32M 153.01M - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.16M 1.34M 0.53M 3.44M 2.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.33M 0.06M 0.14M - -0.01600M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.87M 7.17M 4.65M 4.03M 1.71M
Deferred long term asset charges - - - - -
Non current assets total 1.29M 7.63M 5.72M 5.54M 2.66M
Capital lease obligations 0.40M 0.00000M 0.34M 0.32M 0.16M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -173.89600M -35.99700M -148.41200M -0.61200M -0.19100M
Change to liabilities - - - - 1.73M
Total cashflows from investing activities -173.84100M -35.99700M -148.41200M - -0.19100M
Net borrowings - - - - -
Total cash from financing activities 218.87M 133.16M 234.29M -1.79900M -1.01600M
Change to operating activities - - - - 1.83M
Net income -103.69400M -89.02400M -71.58400M -37.66200M -24.74000M
Change in cash -25.27500M 23.98M 24.61M -34.48800M -20.34100M
Begin period cash flow 124.17M 100.19M 75.59M 110.08M 130.42M
End period cash flow 98.90M 124.17M 100.19M 75.59M 110.08M
Total cash from operating activities -70.30100M -73.19200M -61.26900M -32.07700M -19.13400M
Issuance of capital stock 216.17M 39.19M 0.00000M 0.59M 0.69M
Depreciation 0.26M 0.32M 0.30M 0.21M 0.12M
Other cashflows from investing activities 0.21M 0.87M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.62M - - - -0.22600M
Other cashflows from financing activities 218.87M 93.98M 73.08M -2.39000M -1.48000M
Change to netincome - - - - 1.92M
Capital expenditures 0.16M 0.04M 0.15M 0.61M 0.19M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.12100M -4.54100M 1.40M 0.44M 3.57M
Stock based compensation 34.02M 20.17M 12.91M 3.19M 1.92M
Other non cash items 0.23M -0.11800M -4.29700M 1.74M 2.06M
Free cash flow -70.45900M -73.23600M -61.41800M -32.68900M -19.32500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ELVN
Enliven Therapeutics Inc.		 5.77 14.30% 46.13 - - - 6.04 -6.2821
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 42.01 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

6200 Lookout Road, Boulder, CO, United States, 80301

Key Executives

Name Title Year Born
Mr. Samuel S. Kintz M.B.A. Co-Founder, CEO, Secretary & Director 1986
Mr. Benjamin Hohl CFO & Head of Corporate Development 1989
Dr. Helen Louise Collins M.D. Chief Medical Officer 1963
Dr. Joseph P. Lyssikatos Ph.D. Co-Founder, Chief Scientific Officer & Directors 1965
Mr. Anish Patel Pharm.D. Co-Founder & COO 1980
Dr. Galya D. Blachman Esq., Ph.D. Chief Legal Officer & Head of Business Development 1977
Mr. Samuel S. Kintz M.B.A. Co-Founder & Head of Pipeline 1987
Dr. Joseph P. Lyssikatos Ph.D. Co-Founder & Chief Scientific Officer 1965
Mr. Richard A. Fair CEO, President & Director 1969
Mr. Anish Patel Pharm.D. Co-Founder & COO 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions